PNC Financial Services Group’s CRISPR Therapeutics CRSP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $446K | Sell |
8,173
-29
| -0.4% | -$1.53K | ﹤0.01% | 1872 |
|
|
2026
Q1 | $390K | Buy |
8,202
+489
| +6% | +$25.8K | ﹤0.01% | 1861 |
|
|
2025
Q4 | $404K | Buy |
7,713
+1,082
| +16% | +$64.8K | ﹤0.01% | 1820 |
|
|
2025
Q3 | $430K | Buy |
6,631
+876
| +15% | +$50.3K | ﹤0.01% | 1751 |
|
|
2025
Q2 | $280K | Buy |
5,755
+29
| +0.5% | +$1.12K | ﹤0.01% | 1978 |
|
|
2025
Q1 | $195K | Buy |
5,726
+1,380
| +32% | +$58.5K | ﹤0.01% | 2194 |
|
|
2024
Q4 | $171K | Buy |
4,346
+606
| +16% | +$28.6K | ﹤0.01% | 2327 |
|
|
2024
Q3 | $176K | Sell |
3,740
-604
| -14% | -$30.6K | ﹤0.01% | 2287 |
|
|
2024
Q2 | $235K | Buy |
4,344
+12
| +0.3% | +$694 | ﹤0.01% | 2029 |
|
|
2024
Q1 | $295K | Sell |
4,332
-1,057
| -20% | -$75.7K | ﹤0.01% | 1898 |
|
|
2023
Q4 | $337K | Sell |
5,389
-1,419
| -21% | -$78.4K | ﹤0.01% | 1773 |
|
|
2023
Q3 | $309K | Buy |
6,808
+4,183
| +159% | +$216K | ﹤0.01% | 1813 |
|
|
2023
Q2 | $147K | Buy |
2,625
+97
| +4% | +$5.5K | ﹤0.01% | 2417 |
|
|
2023
Q1 | $114K | Sell |
2,528
-300
| -11% | -$14.6K | ﹤0.01% | 2485 |
|
|
2022
Q4 | $115K | Sell |
2,828
-126
| -4% | -$6.68K | ﹤0.01% | 2485 |
|
|
2022
Q3 | $194K | Buy |
2,954
+126
| +4% | +$9.13K | ﹤0.01% | 2107 |
|
|
2022
Q2 | $172K | Sell |
2,828
-188
| -6% | -$11.1K | ﹤0.01% | 2242 |
|
|
2022
Q1 | $189K | Sell |
3,016
-9,661
| -76% | -$607K | ﹤0.01% | 2297 |
|
|
2021
Q4 | $960K | Sell |
12,677
-518
| -4% | -$45.3K | ﹤0.01% | 1294 |
|
|
2021
Q3 | $1.48M | Buy |
13,195
+219
| +2% | +$27.5K | ﹤0.01% | 1019 |
|
|
2021
Q2 | $2.1M | Sell |
12,976
-465
| -3% | -$56.6K | ﹤0.01% | 904 |
|
|
2021
Q1 | $1.64M | Buy |
13,441
+838
| +7% | +$127K | ﹤0.01% | 965 |
|
|
2020
Q4 | $1.93M | Buy |
12,603
+1,103
| +10% | +$130K | ﹤0.01% | 852 |
|
|
2020
Q3 | $961K | Buy |
11,500
+640
| +6% | +$56.8K | ﹤0.01% | 1057 |
|
|
2020
Q2 | $798K | Sell |
10,860
-10,100
| -48% | -$591K | ﹤0.01% | 1135 |
|
|
2020
Q1 | $888K | Buy |
20,960
+400
| +2% | +$20.7K | ﹤0.01% | 1020 |
|
|
2019
Q4 | $1.25M | Sell |
20,560
-286
| -1% | -$15.6K | ﹤0.01% | 999 |
|
|
2019
Q3 | $855K | Sell |
20,846
-800
| -4% | -$38.2K | ﹤0.01% | 1326 |
|
|
2019
Q2 | $1.02M | Hold |
21,646
| – | – | ﹤0.01% | 1273 |
|
|
2019
Q1 | $774K | Buy |
21,646
+60
| +0.3% | +$2.07K | ﹤0.01% | 1407 |
|
|
2018
Q4 | $616K | Buy |
21,586
+15,868
| +278% | +$552K | ﹤0.01% | 1455 |
|
|
2018
Q3 | $254K | Sell |
5,718
-4,176
| -42% | -$219K | ﹤0.01% | 2065 |
|
|
2018
Q2 | $581K | Buy |
+9,894
| New | +$564K | ﹤0.01% | 1562 |
|
Other funds holding CRSP
IEFM
PNC Financial Services Group's CRSP Position: Q2 2026 in Review
PNC Financial Services Group reduced its CRISPR Therapeutics (CRSP) stake by 0.35% in Q2 2026, selling an estimated $1.53K and leaving 8,173 shares worth $446K. The position accounts for ﹤0.01% of the portfolio, ranked #1872.
PNC Financial Services Group first reported a position in CRSP in Q2 2018 and has held it in 33 quarters since. The position peaked at $2.1M in Q2 2021. 271 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.
- PNC Financial Services Group held 8,173 shares of CRISPR Therapeutics worth $446K as of Q2 2026.
- PNC Financial Services Group sold 29 CRISPR Therapeutics shares in Q2 2026, an estimated $1.53K.
- CRISPR Therapeutics made up ﹤0.01% of PNC Financial Services Group's portfolio in Q2 2026, its #1872 holding.
- PNC Financial Services Group first reported a position in CRISPR Therapeutics in Q2 2018 and has held it in 33 quarters since.
- PNC Financial Services Group's CRISPR Therapeutics position peaked at $2.1M in Q2 2021.
- 271 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.
Based on PNC Financial Services Group's 13F filing for Q2 2026, filed 7 Aug 2026.